Enhanced Recovery After Intensive Care (ERIC)

April 28, 2022 updated by: Claudia Spies, Charite University, Berlin, Germany

Enhanced Recovery After Intensive Care (ERIC) - a Multi-Center Stepped Wedge Cluster-Randomized Controlled Trial

The primary objective of the multi-center stepped-wedge cluster-randomized controlled trial ERIC is to evaluate the effects of a multi-component telemedicine-based intervention delivered by the ICU on the adherence to quality indicators (QI) in intensive care medicine compared to usual care.

Critically ill patients treated on the interventional condition receive daily tele-medical rounds during their ICU stay.

Further secondary objectives are to demonstrate whether the intervention improves patient outcomes 3 and 6 months post ICU discharge, compared to usual care.

Study Overview

Status

Completed

Conditions

Detailed Description

Rationale:

Survivors of critical illness frequently develop long-term mental, cognitive, and/or physical impairments summarized as Post Intensive Care Syndrome (PICS). On the national society level, Germany uses 10 core QIs that are evidence-based to improve treatment quality at ICUs.

Objective:

To investigate whether a tele-medical intervention delivered at ICU improves the adherence to established evidence-based QIs in intensive care medicine compared to the adherence at ICUs delivering usual care.

Study design:

ERIC is a stepped-wedge cluster-randomized controlled quality improvement trial with participating ICUs crossing over from usual care to a multifaceted e-health intervention. After the rollout, all recruiting sites will have implemented the experimental intervention for at least 4 months. Follow-up assessments on the patient-level at month 3 and 6 after ICU discharge (index stay) will be conducted in the outpatient or inpatient setting (dependent on the patient's health status).

Study population:

Critically ill patients covered by statutory health insurance treated at participating ICUs in Berlin and Brandenburg, Germany. It is planned to recruit 1431 study patients within 16 months.

Intervention:

Complex telemedicine-based intervention incorporating the use of e-health technologies (virtual care), supported by blended learning of ICU staff prior to the site's crossover.

Comparison:

Intensive care according to current practice.

Endpoints:

Eight co-primary endpoints will be specified. A primary efficacy endpoint is the adherence to a single QI in intensive care medicine (definition according to Kumpf O. et al., 2017) measured on a daily basis, on a patient-level.

Sedation and delirium management in Frankfurt/Oder before and after implementation of the new form of care ERIC - (SeDelFIN) In this sub-project it should be evaluated how the implementation of the evidence-based standard for delirium, analgesia and pain management changes changed after the introduction of the new form of care. For this purpose, the patient files (which are available in paper form) of all patients who were admitted to the intensive care unit of the Department of Anaesthesiology, Intensive Care Medicine and Pain therapy at the Frankfurt/Oder Clinic (study center) were analyzed by Wilma Klink.

Study Type

Interventional

Enrollment (Actual)

1463

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Berlin, Germany, 12683
        • Unfallkrankenhaus Berlin
      • Berlin, Germany, 10365
        • Sana Klinikum Lichtenberg
      • Berlin, Germany, 12203
        • Department of Anesthesiolgy and Operative Intensive Care Medicine, Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin
      • Berlin, Germany, 13187
        • Maria Heimsuchung Caritas Klinik Pankow
      • Berlin, Germany, 13353
        • Department of Anesthesiolgy and Operative Intensive Care Medicine CCM/CVK, Charité - Universitätsmedizin Berlin
      • Berlin, Germany, 13589
        • Paul Gerhard Diakonie - Evangelisches Waldkrankenhaus Spandau
      • Berlin, Germany, 14129
        • Paul Gerhard Diakonie - Evangelisches Krankenhaus Hubertus
      • Berlin, Germany, 14193
        • Paul Gerhard Diakonie - Martin-Luther-Krankenhaus
      • Eberswalde, Germany, 16225
        • Klinikum Barnim Werner-Forßmann-Krankenhaus
      • Frankfurt (Oder), Germany, 15236
        • Klinikum Frankfurt (Oder)
      • Neuruppin, Germany, 16816
        • Ruppiner Kliniken
      • Potsdam, Germany, 14467
        • Ernst von Bergmann Klinikum - Clinic for Anesthesiology and Operative Intensive Care Medicine
      • Potsdam, Germany, 14467
        • Ernst von Bergmann Klinikum - Clinic for Emergency and Internal-Intensive Care Medicine

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

16 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Patient Level:

Inclusion Criteria:

  • Age ≥ 18 years
  • Expected to receive treatment in a medical or surgical ICU connected to the project for more than 24 hours
  • Coverage by a German statutory health insurance company
  • Written informed consent of patient or legal representative

Exclusion Criteria:

• Age < 18 years

Institutional level:

Inclusion Criteria:

  • Located in the Berlin/Brandenburg metropolitan region
  • Adherence to general legal obligations to participate in the study funded by the German Innovation Fund and participate in the respective contracts.
  • Adherence to cluster-randomization

Exclusion Criteria:

• No intensive care beds available

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: ICU usual care
control condition
The control condition delivered at ICU is usual care.
Experimental: Intervention "ERIC"
intervention condition
The experimental complex intervention ERIC consists of daily tele-medicine based rounds at ICU. Tele-ICU is implemented after a blended learning program for ICU staff which will be completed prior to the site's crossover.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
QI 'Daily multiprofessional and interdisciplinary clinical visits with documentation of daily goals'
Time Frame: From enrolment to ICU discharge; Patients assessed for the duration of their ICU stay after enrolment, expected average of 14 days.
The adherence [fulfilled yes/no] to this intra-hospital QI is daily assessed on a patient-level
From enrolment to ICU discharge; Patients assessed for the duration of their ICU stay after enrolment, expected average of 14 days.
QI 'Management of sedation, analgesia, and delirium'
Time Frame: From enrolment to ICU discharge; Patients assessed for the duration of their ICU stay after enrolment, expected average of 14 days.
The adherence [fulfilled yes/no] to this intra-hospital QI is daily assessed on a patient-level
From enrolment to ICU discharge; Patients assessed for the duration of their ICU stay after enrolment, expected average of 14 days.
QI 'Patient-adapted ventilation'
Time Frame: From enrolment to ICU discharge; Patients assessed for the duration of their ICU stay after enrolment, expected average of 14 days.
The adherence [fulfilled yes/no] to this intra-hospital QI is daily assessed on a patient-level
From enrolment to ICU discharge; Patients assessed for the duration of their ICU stay after enrolment, expected average of 14 days.
QI 'Early weaning from invasive ventilation'
Time Frame: From enrolment to ICU discharge; Patients assessed for the duration of their ICU stay after enrolment, expected average of 14 days.
The adherence [fulfilled yes/no] to this intra-hospital QI is daily assessed on a patient-level
From enrolment to ICU discharge; Patients assessed for the duration of their ICU stay after enrolment, expected average of 14 days.
QI 'Measures for infection management'
Time Frame: From enrolment to ICU discharge; Patients assessed for the duration of their ICU stay after enrolment, expected average of 14 days.
The adherence [fulfilled yes/no] to this intra-hospital QI is daily assessed on a patient-level
From enrolment to ICU discharge; Patients assessed for the duration of their ICU stay after enrolment, expected average of 14 days.
QI 'Early enteral nutrition'
Time Frame: From enrolment to ICU discharge; Patients assessed for the duration of their ICU stay after enrolment, expected average of 14 days.
The adherence [fulfilled yes/no] to this intra-hospital QI is daily assessed on a patient-level
From enrolment to ICU discharge; Patients assessed for the duration of their ICU stay after enrolment, expected average of 14 days.
QI 'Documentation of structured patient and family communications'
Time Frame: From enrolment to ICU discharge; Patients assessed for the duration of their ICU stay after enrolment, expected average of 14 days.
The adherence [fulfilled yes/no] to this intra-hospital QI is daily assessed on a patient-level
From enrolment to ICU discharge; Patients assessed for the duration of their ICU stay after enrolment, expected average of 14 days.
QI 'Early mobilization'
Time Frame: From enrolment to ICU discharge; Patients assessed for the duration of their ICU stay after enrolment, expected average of 14 days.
The adherence [fulfilled yes/no] to this intra-hospital QI is daily assessed on a patient-level
From enrolment to ICU discharge; Patients assessed for the duration of their ICU stay after enrolment, expected average of 14 days.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
All-cause mortality
Time Frame: Up to 6 months following the first study-related ICU admission
Number of deaths from any cause within 6 months after enrolment including in-hospital mortality will be recorded (using hospital administrative records, electronic medical records, municipal personal records database and the 3- and 6-month follow-up with surrogates).
Up to 6 months following the first study-related ICU admission
Mental Health Condition - Depression and Anxiety
Time Frame: 3 and 6 months after ICU discharge
The patient-reported symptom burden on anxiety and depression will be assessed by the paper-based Patient-Health-Questionnaire PHQ-4 at month 3 and 6. Higher total scores indicate higher impairment.
3 and 6 months after ICU discharge
Mental Health Condition - Post-traumatic Stress
Time Frame: 6 months after ICU discharge
Patient-reported symptom burden on post-traumatic stress will be assessed by the paper-based questionnaire Impact of Event Scale revised (IES-R) at month 6. Higher total scores indicate greater distress.
6 months after ICU discharge
Cognition - MiniCog
Time Frame: 3 and 6 months after ICU discharge
Cognitive functional outcome as assessed by the MiniCog test (2 tests: three-item recall task; clock-drawing task) at month 3 and 6. Higher scores indicate better cognitive functioning.
3 and 6 months after ICU discharge
Cognition - Animal Naming Test
Time Frame: 3 and 6 months after ICU discharge
Cognitive functional outcome as assessed by the Animal Naming test at month 3 and 6. Higher scores indicate better cognitive functioning.
3 and 6 months after ICU discharge
Physical Function - Timed Up & Go Test
Time Frame: 3 and 6 months after ICU discharge
Patient's physical function, walking ability and risk of fall as assessed by the Timed Up & Go (TUG) test at month 3 and 6. Higher scores indicate a higher level of impairment.
3 and 6 months after ICU discharge
Physical Function - Hand grip strength test
Time Frame: 3 and 6 months after ICU discharge
Patient's muscle/ nerve function is assessed by the Hand grip strength (HGS) test (measured with a dynamometer, average strength [in kg] of three trials for the dominant hand) at months 3 and 6.
3 and 6 months after ICU discharge
Health-related quality of life
Time Frame: 3 and 6 months after ICU discharge
Patient's self-reported health-related quality of life as measured by the EuroQol - 5 Dimensions - 5 Level (EQ-5D-5L) Visual Analogue Scale (VAS) and the EQ-5D-5L descriptive system; the EQ-5D-5L VAS is a thermometer-like rating scale ranging from 0 (worst imaginable health state) to 100 (best imaginable health state).
3 and 6 months after ICU discharge
Organ dysfunction
Time Frame: 3 and 6 months after ICU discharge
Number of patients with organ dysfunction as assessed by general practitioner or study personnel/ investigator at month 3 and 6.
3 and 6 months after ICU discharge
Pulmonary Function - Dyspnea
Time Frame: 6 months after ICU discharge
Self-perceived breathlessness as assessed by the Modified British Medical Research Council (mMRC) Dyspnea Scale at month 6. 5-point Likert scale [range 1 to 5] with a higher score indicating higher impairment.
6 months after ICU discharge
Outpatient ventilation
Time Frame: Up to 6 months after ICU discharge
Duration [in days] of mechanical ventilation after discharge from the ICU
Up to 6 months after ICU discharge
Patient-reported Functioning and Disability (WHO Disability Assessment Schedule).
Time Frame: 6 months after ICU discharge
Patient-reported General Disability Score as measured by the WHO Disability Assessment Schedule (WHODAS 2.0) for activity limitation and participation restriction, 12-item short version, self-administered questionnaire. The raw score is calculated by summing the values for each of the 12 questions. Higher scores indicate greater disability.
6 months after ICU discharge

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Economic - Length of stay at intensive care unit
Time Frame: Up to 6 months
Patients will be followed for duration of stay. The total number of days spent in ICU will be assessed (inclusive of index ICU stay).
Up to 6 months
Economic - Length of hospital stay
Time Frame: Up to 6 months
Patients will be followed for duration of hospital stay. The total number of days spent in a hospital will be assessed (inclusive of index ICU stay and index hospitalization).
Up to 6 months
Economic - Return to work
Time Frame: 3 and 6 months after ICU discharge
Employment status at 3 months and 6 months after hospital discharge (including e.g. return to work, change in duties or change in effectiveness) at 3 and 6 months.
3 and 6 months after ICU discharge
Economic - Cost-effectiveness
Time Frame: 3 and 6 months after ICU discharge
Health-related costs for standard care and supportive care will be estimated in Euros per patient per months. Data source will be GPs, hospital-electronic health records and health insurance data as well as publicly available data sources from the German reimbursement system.
3 and 6 months after ICU discharge

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 4, 2018

Primary Completion (Actual)

April 15, 2020

Study Completion (Actual)

November 17, 2020

Study Registration Dates

First Submitted

August 22, 2018

First Submitted That Met QC Criteria

September 12, 2018

First Posted (Actual)

September 14, 2018

Study Record Updates

Last Update Posted (Actual)

May 4, 2022

Last Update Submitted That Met QC Criteria

April 28, 2022

Last Verified

April 1, 2022

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Critical Illness

Clinical Trials on ICU Usual Care

3
Subscribe